Learning objectives

After watching this webinar, participants will be able to:

understand that CK-MB was the preferred biomarker for detection of cardiomyocyte injury and AMI prior to the development of cTn assays;
appreciate the different kinetics of CK-M vs. cTn;
know that current hs-cTnT/I assays have much higher sensitivity and diagnostic accuracy vs. CK-MB, obviating the use of CK-MB; and
appreciate remaining uncertainties in the early detection re-infarction.